Prokinetic agents and QT prolongation: A familiar scene with new actors

Current Drug Safety

Volumn 5, Issue 1, 2010, Pages 73-78

  Keller, Guillermo Alberto ^a   Di Girolamo, Guillermo ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b FAVALORO UNIVERSITY   (Argentina)

Author keywords

Cisapride; Long QT syndrome; Mosapride; Pharmacovigilance; Prokinetic agents; Torsades de pointes

Indexed keywords

CIMETIDINE; CINITAPRIDE; CISAPRIDE; CLARITHROMYCIN; DIAZEPAM; DOMPERIDONE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; ERYTHROMYCIN; FLUCONAZOLE; GLYCOPROTEIN P; HYDROXYITRACONAZOLE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; METOCLOPRAMIDE; MIBEFRADIL; MICONAZOLE; MOSAPRIDE CITRATE; NEFAZODONE; PROKINETIC AGENT; PRUCALOPRIDE; RANITIDINE; RITONAVIR; SEROTONIN 4 RECEPTOR; SULPIRIDE; TEGASEROD; TROLEANDOMYCIN; UNINDEXED DRUG;

ACTION POTENTIAL; ARRHYTHMOGENESIS; CENTRAL NERVOUS SYSTEM; CHRONOTROPISM; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPEPSIA; ELECTROPHYSIOLOGY; ENZYME INHIBITION; GASTRIC DYSMOTILITY; GASTROESOPHAGEAL REFLUX; HEART INFARCTION; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; IC 50; POLYURIA; POSTMARKETING SURVEILLANCE; POTASSIUM CURRENT; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STOMACH EMPTYING; STROKE; SUDDEN DEATH; TORSADE DES POINTES; UNSTABLE ANGINA PECTORIS; URINE INCONTINENCE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; BIOLOGICAL AVAILABILITY; CISAPRIDE; DRUG INTERACTIONS; GASTROINTESTINAL AGENTS; HUMANS; LONG QT SYNDROME; P-GLYCOPROTEIN; RISK FACTORS; SEROTONIN AGONISTS;

EID: 77950846304     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610789869166     Document Type: Review

References (82)

1. Janssen. Summary of Product Characteristics: cisapride (PREPULSID). In ABPI Compendium of Data Sheets, Association of British Pharmaceutical Industry (ed.). 1991.
2. Olshansky B, Martins J, Hunt S. N-acetyl procainamide causing torsades de pointes. Am J Cardiol 1982; 50: 1439-1441
3. Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97: 204-210
4. Waller P, Lee E. Responding to drug safety issues. Pharmacoepidemiol Drug Saf 1999; 8: 535-552
5. Article 25 of European Council Regulation (EEC). 2309/93. 2001.
6. Olsson S. The role of the WHO programme on International Drug Monitoring in co-ordinating worldwide drug safety efforts. Drug Saf 1998; 19: 1-10.
7. Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16: 355-365
8. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991; 83: 1888-1894
9. Olsson S, Edwards IR. Tachycardia during cisapride treatment. Br Med J 1992; 305: 748-749
10. Hirst C, Cook S, Dai W, Perez-Gutthann S, Andrews E. A call for international harmonization in therapeutic risk management. Pharmacoepidemiol Drug Saf 2006; 15: 839-849
11. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96: 1698-1703
12. Levine A, Fogelman R, Sirota L, Zangen Z, Shamir R, Dinari G. QT interval in children and infants receiving cisapride. Pediatrics 1998; 101: E9.
13. Walker AM, Szneke P, Weatherby LB, et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999; 107: 356-362
14. Enger C, Cali C, Walker A.M. Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidemiol Drug Saf 2002; 11: 477-486
15. Zheng ZJ, Croft JB, Giles WH, et al. State-specific mortality from sudden cardiac death - United States, 1999. Morb Mortal Wkly Rep 2002; 51: 123-126
16. Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W, Moyé L. Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 1994; 73: 346-352
17. Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. Br Med J 2002; 325: 1070.
18. Hennessy S, Leonard CE, Newcomb C, Kimmel SE, Bilker W.B. Cisapride and ventricular arrhytmia. Br J Clin Pharmacol 2008; 66(3): 375-385
19. Eglen RM, Wong EHF, Dumuis A, Bockaert J. Central 5-HT4 receptors. Trends Pharmacol Sci 1995; 16: 391-398
20. Pau D, Workman AJ, Kane KA, Rankin AC. Electrophysiological effects of 5-hydroxytryptamine on isolated human atrial myocytes, and the influence of chronic beta-adrenoceptor blockade. Br J Pharmacol 2003; 140(8): 1434-1441
21. Kaumann AJ, Sanders L. 5-Hydroxytryptamine causes ratedependent arrhythmias through 5-HT4 receptor in human atrium: facilitation by chronic b-adrenoceptor blockade. Naunyn- Schmiedeberg's Arch Pharmacol 1994; 349: 331-337
22. Kaumann AJ, Lynham JA, Brown A.M. Comparison of the densities of 5-HT4 receptors, b1- and b2-adrenoceptors in human atrium: functional implications. Naunyn-Schmiedeberg's Arch Pharmacol 1996; 353: 592-595
23. Lefebvre H, Gonzalez KN, Contesse V, Delarue C, Vaudry H, Kuhnl J.M. Effect of prolonged administration of the serotonin4 (5-HT4) receptor agonist cisapride on aldosterone secretion in healthy volunteers. Endocr Res 1998; 24: 749-752
24. Lefebvre H, Heron F, Contesse V, Delarue C, Vaudry H, Kuhn J.M. Effect of the serotonin4 receptor agonist cisapride on plasma aldosterone levels in cirrhotic patients with secondary hyperaldosteronism. Eur J Clin Pharmacol 1998; 53: 479-480
25. Tonini M, Messori E, Franceschetti GP, et al. Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. Br J Pharmacol 1994; 113: 1-2.
26. Candura SM, Messori E, Franceschetti GP, et al. Neural 5-HT4 receptors in the human isolated detrusor muscle: effects of indole, benzimidazolone and substituted benzamide agonists and antagonists. Br J Pharmacol 1996; 118: 1965-1970.
27. Boyd IW, Rohan AP. Urinary disorders associated with cisapride. Med J Aust 1994; 160: 579-580
28. Pillans PI, Wood MD. Cisapride increases micturition frequency. J Clin Gastroenterol 1994; 19: 336-346
29. Tonini M, Candura SM. 5-HT4 receptor agonists and bladder disorders. Trends Pharmacol Sci 1996; 17: 314-316
30. Kaumann AJ. Do human atrial 5-HT4 receptors mediate arrhythmias? Trends Pharmacol Sci 1994; 15: 451-455
31. Ahmad SR, Wolfe SM. Cisapride and torsades de pointes. Lancet 1995; 345: 508-512
32. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335: 290-291
33. Morgan TK, Sullivan ME. An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. Progr Med Chem 1992; 29: 65-108.
34. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential. J Pharmacol Exp Ther 1997; 282: 220-227
35. Drici MD, Ebert SN, Wang WX, et al. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization and the isolated rabbit heart. J Cardiovasc Pharmacol 1999; 34: 82-88
36. Kii Y, Ito T. Effects of 5-HT4 receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. J Cardiovasc Pharmacol 1997; 29: 670-675
37. Claassen S, Zünkler BJ. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology 2005; 74(1): 31-36
38. Drolet B, Rousseau G, Daleau P, Cardinal R, Turgeon J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 1988; 102: 1883-1885
39. Robert M, Salvà M, Segarra R, et al. The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. Drug Metab Dispos 2007; 35(7): 1149-1156
40. Dresser GK, Spence JD, Bailey DG. Pharmacokineticpharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38(1): 41-57.
41. Crumb WJ (2000) Herg blocking profile of SD-33 (cinitapride). Data on File, Almirall Prodesfarma, S.A., Barcelona.
42. Kiehn J, Thomas D, Karle CA, SchoÈls W, KuÈ bler W. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn-Schmiedeberg's Arch Pharmacol 1999; 359: 212-219
43. Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999; 10: 272-282
44. Montaz L, Varache N, Harry P, et al. Torsades de pointes during sultopride poisoning. J Toxicol Clin Exp 1992; 12: 481-496
45. Tracqui A, Mutter-Schmidt C, Kintz P, Berton C, Mangin P. Amisulpride poisoning: a report on two cases. Hum Exp Toxicol 1995; 14: 294-298
46. Adamantidis MM, Kerram P, Dupuis BA. In vitro electrophysiological detection of iatrogenic arrhythmogenicity. Fundam Clin Pharmacol 1994; 8: 391-407.
47. Malkoff MD, Ponzillo JJ, Myles GL, Gomez CR, Cruz-Flores S. Sinus arrest after administration of intravenous metoclopramide. Ann Pharmacother 1995; 29: 381-383
48. Mohammad S, Zhou Z, Gong Q, January CT. Blockage of the HERG human cardiac Kp channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997; 273: H2534-8.
49. Puisieux FL, Adamantidis MM, Dumotier BM, Dupuis BA. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996; 117: 1377-1379
50. Rampe D, Roy M-L, Dennis A, Brown A.M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997; 417: 28-32.
51. Wager E, Tooley PJ, Pearce GL, Wilton LV, Mann RD. A comparison of two cohort studies evaluating the safety of cisapride: prescription-event monitoring and a large phase IV study. Eur J Clin Pharmacol 1997; 52: 87-94.
52. Lewin MB, Bryant RM, Fenrich AL, Grifka RG. Cisapride-induced long QT interval. J Pediatr 1996; 128: 279-281
53. Khongphatthanayothin A, Lane J, Thomas D, Yen L, Chang D, Bubolz B. Effects of cisapride on QT interval in children. J Pediatr 1998; 133: 51-56
54. Autret E, Jonville-Bera AP, Champel V. Cardiac poisoning of cisapride (Prepulsid) must be considered in its prescription, specially in premature infants. Arch Pediatr 1997; 4: 507-508
55. Gray VS. Syncopal episodes associated with cisapride and concurrent drugs. Ann Pharmacother 1998; 32: 648-651
56. Bedford TA, Rowbotham DJ. Cisapride drug interactions of clinical significance. Drug Saf 1996; 15: 167-175
57. Doig J.C. Drug-induced cardiac arrhythmias: incidence, prevention and management. Drug Saf 1997; 17: 265-275
58. van Haarst AD, van 't Klooster GA, van Gerven JM, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998; 64: 542-546
59. Pipkin GA, Williamson R, Wood JR. Review article: oneweek clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Alim Pharmacol Ther 1998; 12: 823-837
60. Gascon MP, Dayer P. Comparative effects of macrolide antibiotics on liver monoxygenases. Clin Pharmacol Ther 1991; 49: 158.
61. Tinel M, Descatoire V, Larrey D, et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989; 250: 746-751
62. Honig PK, Wortham DC, Zamani K, Cantilena L.R. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994; 7: 148-156
63. Von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995; 13: 105-122
64. Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors of human cytochrome P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-111
65. Meuldermans W, Van Peer A, Hendrickx J, et al. Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metab Dispos 1988; 16:403-409
66. Bohets K, Lavrijsen J, Hendrickx K, et al. Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol 2000; 129:1655-1667
67. Rowbotham DJ, Milligan K, Mchugh P. Effect of cisapride on morphine absorption after oral administration of sustained-release morphine. Br J Anaesth 1991; 67:421-425
68. Bateman DN. The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. Eur J Clin Pharmacol 1986; 30: 205-208
69. Periti O, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23:106-131
70. Gross AJ, Goh YD, Addison RS, Shenfield CM. Influence of grapefruit juice on cisapride pharmacokinetics. Clin Pharmacol Ther 1999; 64:395-401.
71. Food and Drug Administration advisory commitee. FDA Talk paper. 23rd March 2000.
72. Committee on Safety of Medicine. Cisapride (Prepulsid) withdrawn. Curr Problems Pharmacovigilance 2000; 26: 1.
73. Barbey JT, Lazzara R, Zipes DP. Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther 2002;7: 65-76.
74. Iglesias E, Esteban E, Zabala S, Gascon A. Tiapride-induced torsade de pointes. Am J Med 2000; 109 (6): 509.
75. Bruera E, villamayor R, Roca E, Barugel M, Tronge J, Chacon R. QT interval prolongation and ventricular fibrillation with i.v. domperidone. Cancer Treat Rep 1986; 70(4): 545-546
76. Osborne RJ, Slevin ML, Hunter RW, Hamer J. Cardiac Arrhytmias during cytotoxic chemotherapy: role of domperidone. Hum Toxicol 1985; 4(6): 617-626
77. Cameron HA, Reyntjens AJ, Lake-Bakaar G. Cardiac arrest after treatment with intravenous domperidone. Br Med J 1985; 290(6462): 160.
78. Quinn N, Parkes D, Jackson G, Upward J. Cardiotoxicity of domperidone. Lancet 1985; 2(8457): 724.
79. Osborne RJ, Slevin ML, Hunter RW, Hamer J. Cardiotoxicity of intravenous domperidone. Lancet 1985; 2(8451): 385.
80. Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. Br Med J 1984; 289: 1579.
81. Giaccone G, Berletto O, Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet 1984; 2: 1336-1337
82. Joss RA, Goldhirsh A, Brunner KW, Galeazzi RL, Sudden death in a cancer patient on high dose domperidone. Lancet 1982; 1(8279): 1019.